{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T05:33:04Z","timestamp":1793079184213,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.kint.2026.08.020","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:35:32Z","timestamp":1790177732000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel human neutralizing monoclonal antibodies against pregnancy-associated plasma protein A for the treatment of autosomal dominant polycystic kidney disease"],"prefix":"10.1016","author":[{"given":"Erding","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Gardener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guizhen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuck","family":"Kotzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Mallick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Ouro-Gnao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Firczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Chandler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-wa","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panchali","family":"Goswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saaussan","family":"Madi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Lenhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6600-2146","authenticated-orcid":false,"given":"Hasan","family":"Alsaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh","family":"Doan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavini","family":"Nanayakkara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel I.","family":"Swerdlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente E.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2S","key":"10.1016\/j.kint.2026.08.020_bib1","first-page":"S1","article-title":"KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD)","volume":"107","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.08.020_bib2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41572-018-0047-y","article-title":"Polycystic kidney disease","volume":"4","author":"Bergmann","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.kint.2026.08.020_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109649","article-title":"Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling","volume":"72","author":"Sussman","year":"2020","journal-title":"Cell Signal"},{"key":"10.1016\/j.kint.2026.08.020_bib4","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.08.020_bib5","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.08.020_bib6","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.2215\/CJN.03530411","article-title":"Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience","volume":"6","author":"Higashihara","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.08.020_bib7","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/jcph.880","article-title":"Pharmacokinetics and pharmacodynamics of tolvaptan in autosomal dominant polycystic kidney disease: phase 2 trials for dose selection in the pivotal phase 3 trial","volume":"57","author":"Shoaf","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.kint.2026.08.020_bib8","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1053\/j.ajkd.2022.08.012","article-title":"Clinical pattern of tolvaptan-associated liver injury in trial participants with autosomal dominant polycystic kidney disease (ADPKD): an analysis of pivotal clinical trials","volume":"81","author":"Alpers","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.08.020_bib9","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.135700","article-title":"Metalloproteinase PAPP-A regulation of IGF-1 contributes to polycystic kidney disease pathogenesis","volume":"5","author":"Kashyap","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.kint.2026.08.020_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109698","article-title":"Implications of the PAPP-A-IGFBP-IGF-1 pathway in the pathogenesis and treatment of polycystic kidney disease","volume":"73","author":"Kashyap","year":"2020","journal-title":"Cell Signal"},{"key":"10.1016\/j.kint.2026.08.020_bib11","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1210\/endrev\/bnad017","article-title":"The pregnancy-associated plasma protein-A (PAPP-A) story","volume":"44","author":"Conover","year":"2023","journal-title":"Endocr Rev"},{"key":"10.1016\/j.kint.2026.08.020_bib12","doi-asserted-by":"crossref","first-page":"16772","DOI":"10.1074\/jbc.M802429200","article-title":"Inhibition of the proteolytic activity of pregnancy-associated plasma protein-A by targeting substrate exosite binding","volume":"283","author":"Mikkelsen","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.kint.2026.08.020_bib13","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13313","article-title":"Inhibition of longevity regulator PAPP-A modulates tissue homeostasis via restraint of mesenchymal stromal cells","volume":"20","author":"Mohrin","year":"2021","journal-title":"Aging Cell"},{"key":"10.1016\/j.kint.2026.08.020_bib14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/19420862.2016.1246096","article-title":"Broad epitope coverage of a human in vitro antibody library","volume":"9","author":"Sivasubramanian","year":"2017","journal-title":"MAbs"},{"key":"10.1016\/j.kint.2026.08.020_bib15","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3390\/biom13040694","article-title":"Biological screening and crystallographic studies of hydroxy \u03b3-lactone derivatives to investigate PPAR\u03b3 phosphorylation inhibition","volume":"13","author":"Capelli","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.kint.2026.08.020_bib16","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1210\/jc.2015-2196","article-title":"IGFBP-4 fragments as markers of cardiovascular mortality in type 1 diabetes patients with and without nephropathy","volume":"100","author":"Hjortebjerg","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.kint.2026.08.020_bib17","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/ki.1993.151","article-title":"Juvenile cystic kidneys (jck): a new mouse mutation which causes polycystic kidneys","volume":"43","author":"Atala","year":"1993","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.08.020_bib18","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.kint.2023.07.021","article-title":"Certain heterozygous variants in the kinase domain of the serine\/threonine kinase NEK8 can cause an autosomal dominant form of polycystic kidney disease","volume":"104","author":"Claus","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.08.020_bib19","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1681\/ASN.2006020136","article-title":"Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease","volume":"17","author":"Smith","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.08.020_bib20","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1172\/JCI64313","article-title":"Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity","volume":"122","author":"Hopp","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kint.2026.08.020_bib21","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.kint.2021.01.028","article-title":"The genetic background significantly impacts the severity of kidney cystic disease in the Pkd1(RC\/RC) mouse model of autosomal dominant polycystic kidney disease","volume":"99","author":"Arroyo","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.08.020_bib22","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.18632\/oncotarget.1629","article-title":"Indirect targeting of IGF receptor signaling in vivo by substrate-selective inhibition of PAPP-A proteolytic activity","volume":"5","author":"Mikkelsen","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.kint.2026.08.020_bib23","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41421-022-00502-2","article-title":"Structural insights into the covalent regulation of PAPP-A activity by proMBP and STC2","volume":"8","author":"Zhong","year":"2022","journal-title":"Cell Discov"},{"key":"10.1016\/j.kint.2026.08.020_bib24","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.21037\/jtd-21-551","article-title":"Anticancer mechanism of breviscapine in non-small cell lung cancer A549 cells acts via ROS-mediated upregulation of IGFBP4","volume":"13","author":"Wei","year":"2021","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.kint.2026.08.020_bib25","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/1816504","article-title":"CT-IGFBP-4 as a predictive novel biomarker of ischemic cardiovascular events and mortality: a systematic review","volume":"2022","author":"Bhattarai","year":"2022","journal-title":"J Interv Cardiol"},{"key":"10.1016\/j.kint.2026.08.020_bib26","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1038\/s41467-022-33698-8","article-title":"Structure of the proteolytic enzyme PAPP-A with the endogenous inhibitor stanniocalcin-2 reveals its inhibitory mechanism","volume":"13","author":"Kobber\u00f8","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2026.08.020_bib27","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2215\/CJN.06300615","article-title":"Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: results from the TEMPO 3:4 trial","volume":"11","author":"Torres","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.08.020_bib28","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00467-014-2882-8","article-title":"Rationale for early treatment of polycystic kidney disease","volume":"30","author":"Grantham","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2026.08.020_bib29","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.3390\/cells10123371","article-title":"Growth hormone and IGF1 actions in kidney development and function","volume":"10","author":"Gurevich","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.kint.2026.08.020_bib30","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1172\/JCI115119","article-title":"Effects of recombinant human insulin-like growth factor I on glomerular dynamics in the rat","volume":"87","author":"Hirschberg","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kint.2026.08.020_bib31","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1172\/JCI113878","article-title":"Evidence that insulin-like growth factor I increases renal plasma flow and glomerular filtration rate in fasted rats","volume":"83","author":"Hirschberg","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kint.2026.08.020_bib32","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0272-6386(12)81085-7","article-title":"Growth hormone-induced glomerular hyperfiltration is dependent on vasodilating prostanoids","volume":"21","author":"Tonshoff","year":"1993","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.08.020_bib33","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1210\/endo-123-6-2827","article-title":"Growth enhancement of transgenic mice expressing human insulin-like growth factor I","volume":"123","author":"Mathews","year":"1988","journal-title":"Endocrinology"},{"key":"10.1016\/j.kint.2026.08.020_bib34","first-page":"398","article-title":"Progressive glomerulosclerosis develops in transgenic mice chronically expressing growth hormone and growth hormone releasing factor but not in those expressing insulinlike growth factor-1","volume":"131","author":"Doi","year":"1988","journal-title":"Am J Pathol"},{"key":"10.1016\/j.kint.2026.08.020_bib35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/nep.12198","article-title":"Compensatory responses to nephron deficiency: adaptive or maladaptive?","volume":"19","author":"Fong","year":"2014","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.kint.2026.08.020_bib36","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1001\/jama.2018.15870","article-title":"Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: the DIPAK 1 randomized clinical trial","volume":"320","author":"Meijer","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2026.08.020_bib37","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1002\/art.21975","article-title":"A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis","volume":"54","author":"Haringman","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.kint.2026.08.020_bib38","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/s41416-020-0774-1","article-title":"Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours","volume":"122","author":"de Bono","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.kint.2026.08.020_bib39","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1042\/CS20080140","article-title":"Gender and renal function influence plasma levels of copeptin in healthy individuals","volume":"116","author":"Bhandari","year":"2009","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.kint.2026.08.020_bib40","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1097\/HJH.0000000000000610","article-title":"Plasma copeptin levels and ambulatory blood pressure characteristics in healthy adults","volume":"33","author":"Schoen","year":"2015","journal-title":"J Hypertens"},{"key":"10.1016\/j.kint.2026.08.020_bib41","doi-asserted-by":"crossref","first-page":"R700","DOI":"10.1152\/ajpregu.00500.2006","article-title":"Sex difference in urine concentration across differing ages, sodium intake, and level of kidney disease","volume":"292","author":"Perucca","year":"2007","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.kint.2026.08.020_bib42","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/00000441-198804000-00017","article-title":"Vasopressin: sexual dimorphism in secretion, cardiovascular actions and hypertension","volume":"295","author":"Share","year":"1988","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.kint.2026.08.020_bib43","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1507\/endocrj1954.35.267","article-title":"Effect of ovarian steroids on cyclic adenosine 3':5'-monophosphate production stimulated by arginine vasopressin in rat renal monolayer cultured cells","volume":"35","author":"Hatano","year":"1988","journal-title":"Endocrinol Jpn"},{"key":"10.1016\/j.kint.2026.08.020_bib44","first-page":"R951","article-title":"Estradiol attenuates the antidiuretic action of vasopressin in ovariectomized rats","volume":"268","author":"Wang","year":"1995","journal-title":"Am J Physiol"},{"key":"10.1016\/j.kint.2026.08.020_bib45","doi-asserted-by":"crossref","first-page":"F433","DOI":"10.1152\/ajprenal.00199.2010","article-title":"Sex differences in vasopressin V(2) receptor expression and vasopressin-induced antidiuresis","volume":"300","author":"Liu","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2026.08.020_bib46","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.kint.2026.04.021","article-title":"Effectiveness and mechanistic effects of green mamba related peptide MQ232 in an orthologous mouse model of autosomal dominant polycystic kidney disease","volume":"110","author":"Wang","year":"2026","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.08.020_bib47","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1177\/1535370213489437","article-title":"Follicle growth, ovulation, and luteal formation in primates and rodents: a comparative perspective","volume":"238","author":"Chaffin","year":"2013","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.kint.2026.08.020_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914882","article-title":"The IGF1 signaling pathway: from basic concepts to therapeutic opportunities","volume":"24","author":"Werner","year":"2023","journal-title":"Int J Mol. Sci"},{"key":"10.1016\/j.kint.2026.08.020_bib49","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.bbrc.2007.05.062","article-title":"The insulin-like growth factor 1 (IGF-1) receptor is a substrate for gamma-secretase-mediated intramembrane proteolysis","volume":"358","author":"McElroy","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.kint.2026.08.020_bib50","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10911-008-9098-0","article-title":"Crosstalk between IGF1R and estrogen receptor signaling in breast cancer","volume":"13","author":"Fagan","year":"2008","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"10.1016\/j.kint.2026.08.020_bib51","first-page":"345","article-title":"Insulin-like growth factor\u2014oestradiol crosstalk and mammary gland tumourigenesis","volume":"1836","author":"Hawsawi","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.kint.2026.08.020_bib52","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.tem.2005.06.010","article-title":"Estrogen rapid action via protein complex formation involving ERalpha and Src","volume":"16","author":"Song","year":"2005","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.kint.2026.08.020_bib53","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1093\/emboj\/20.21.6050","article-title":"PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells","volume":"20","author":"Castoria","year":"2001","journal-title":"EMBO J"},{"key":"10.1016\/j.kint.2026.08.020_bib54","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1210\/endo.142.12.8546","article-title":"Estradiol (E2) elicits SRC phosphorylation in the mouse neocortex: the initial event in E2 activation of the MAPK cascade?","volume":"142","author":"Nethrapalli","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.kint.2026.08.020_bib55","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/1471-2407-12-291","article-title":"Ligand-free estrogen receptor activity complements IGF1R to induce the proliferation of the MCF-7 breast cancer cells","volume":"12","author":"Gaben","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.kint.2026.08.020_bib56","article-title":"Interplay of IGF1R and estrogen signaling regulates hematopoietic stem and progenitor cells","author":"Xie","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.kint.2026.08.020_bib57","doi-asserted-by":"crossref","first-page":"F726","DOI":"10.1152\/ajprenal.00551.2015","article-title":"A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease","volume":"310","author":"Kipp","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2026.08.020_bib58","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1681\/ASN.2015020132","article-title":"Food restriction ameliorates the development of polycystic kidney disease","volume":"27","author":"Warner","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.08.020_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103697","article-title":"Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease","volume":"25","author":"Hopp","year":"2022","journal-title":"iScience"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826008070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826008070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T05:00:17Z","timestamp":1793077217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253826008070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":59,"alternative-id":["S0085253826008070"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2026.08.020","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel human neutralizing monoclonal antibodies against pregnancy-associated plasma protein A for the treatment of autosomal dominant polycystic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}